echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Transl Lung Cancer Res: Safety and efficacy of nivolumab combined with recombinant human endostatin in the treatment of previously treated advanced non-small cell lung cancer

    Transl Lung Cancer Res: Safety and efficacy of nivolumab combined with recombinant human endostatin in the treatment of previously treated advanced non-small cell lung cancer

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Evidence for the efficacy of immune checkpoint inhibitors (ICIs) in combination with antiangiogenic agents in previously treated patients with advanced non-small cell lung cancer (NSCLC) remains insufficient
    .


    Recently, a team from the Fifth Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the safety and efficacy of nivolumab (nivolumab) combined with recombinant human endostatin in previously treated advanced non-small cell lung cancer (NSCLC)


    Evidence for the efficacy of immune checkpoint inhibitors (ICIs) in combination with antiangiogenic agents in previously treated patients with advanced non-small cell lung cancer (NSCLC) remains insufficient


    The study included patients with EGFR/ALK-negative advanced NSCLC who progressed after previous therapy
    .


    Eligible patients received nivolumab (3 mg/kg, IV infusion, Day 1) every 2 weeks and recombinant human endostatin (210 mg, continuous IV infusion for 168 h) every 4 weeks until disease progression or discontinuation of treatment


    The study included patients with EGFR/ALK-negative advanced NSCLC who progressed after previous therapy


    Thirty-four patients were included, with a median age of 60 years (range 37-72 years), 26.


    Thirty-four patients received a median of 4 cycles of treatment


    Median follow-up was 12.
    2 months (range, 2.
    3-18.
    1 months)
    .


    Median PFS (mPFS) was 6.


    Median follow-up was 12.


    Compared with patients with ECOG PS=2, patients with ECOG PS=0-1 had longer mPFS (12.
    5 vs 1.
    7 months; p<0.
    001) and mOS (17.
    1 months vs 3.
    4 months; p<0.
    001)
    .


    Likewise, patients with ≤ two metastases achieved longer mPFS (9.


    Compared with patients with ECOG PS=2, patients with ECOG PS=0-1 had longer mPFS (12.


    Eighteen (18/34, 52.
    9%) patients had at least one treatment-related adverse event (TRAE), of which 4 (4/34, 11.
    8%) had a grade 3 TRAE
    .

    Eighteen (18/34, 52.
    9%) patients had at least one treatment-related adverse event (TRAE), of which 4 (4/34, 11.
    8%) had a grade 3 TRAE
    .


    In conclusion, this study is the first to evaluate the effect of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
    .


    Given its favorable efficacy and safety profile, this combination is a promising treatment option
    .

    In conclusion, this study is the first to evaluate the effect of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
    .
    Given its favorable efficacy and safety profile, this combination is a promising treatment option
    .
    This study is the first to assess the effects of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
    .
    Given its favorable efficacy and safety profile, this combination is a promising treatment option
    .
    This study is the first to assess the effects of nivolumab plus recombinant human endostatin in previously treated patients with advanced NSCLC
    .
    Given its favorable efficacy and safety profile, this combination is a promising treatment option
    .

     

    Original source:

    Original source:

    Lv W, Pei X, Zhao W, Cong Y, Wei Y, Li T, Zhang H, Lin Z, Saito Y, Kim JJ, Liang Z, Zhong B, Wang Z.
    Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
    Transl Lung Cancer Res.
    2022 Feb;11(2):201-212.
    doi: 10.
    21037/tlcr-22-49.
    PMID: 35280309; PMCID: PMC8902090.

    Lv W, Pei X, Zhao W, Cong Y, Wei Y, Li T, Zhang H, Lin Z, Saito Y, Kim JJ, Liang Z, Zhong B, Wang Z.
    Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
    Transl Lung Cancer Res.
    2022 Feb;11(2):201-212.
    doi: 10.
    21037/tlcr-22-49.
    PMID: 35280309; PMCID: PMC8902090.

     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.